CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc., (7SBio), a leading developer of blood collection and diagnostic platforms, announced today the receipt of notices of allowance from the United States Patent and Trademark Office for three patent applications (U.S. Patent Applications 13/680,351, 13/456,570, and 13/292,254).
The allowed claims cover blood collection devices including TAP devices for the collection of any volume of blood and the use of microneedles, microfluidics and a vacuum to cause blood flow. These patent allowances are paramount to protecting and building out 7SBio’s proprietary Touch Activated Phlebotomy (TAP) technology platform and the core design of the TAP devices.
“We are thrilled to have reached this critical milestone on our steady path towards the commercialization of our devices,” said Howard Weisman, CEO at 7SBio. “We continue to make meaningful progress towards transforming blood testing so that it is more comfortable, manageable and ubiquitous for patients. With more than 40 percent of the population reported to be in non-compliance with their blood test requisitions due to fear of a venipuncture or finger stick, the potential impact of a patented system that is essentially pain-free is enormous and life changing for millions of individuals. We are another large step closer to that reality today.”
7SBio received its first patent in October of 2013 for low-pressure packaging for fluid devices (Issued U.S. Patent 8,561,795). This patent covered combinations of blood collection devices packaged under vacuum in a wide variety of materials that increase product stability. The company expects a broad array of other patents related to blood collection and diagnostics to issue in the near future.
About the TAP Touch Activated Phlebotomy ™ and TAP Devices
TAP is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein, and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.
About Seventh Sense Biosystems, Inc.
Founded in 2008, Seventh Sense Biosystems is developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. The company’s initial focus is on improving important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection. 7SBio receives funding from investors Flagship Venture Partners, Lighthouse Capital Partners, and Polaris Partners. For more information, please visit www.7sbio.com.